CEO Sean A. McCarthy sold 118,969 shares of CTMX at $6.42 on 2026-03-17; stock now $4.78. Company unprofitable, revenue down -44.8% YoY.
CEO Sean A. McCarthy sold 118,969 shares at $6.42, reducing holdings by 9.9% to 1,078,922 shares post-transaction. The sale occurred near the 52-week high of $6.75, with the stock subsequently declining to $4.78 (currently -29.2% from its peak). CytomX is unprofitable with net income of $-14,229,000.00 and experienced severe revenue contraction of -44.8% year-over-year to $5,963,000.00 in the latest quarter. The magnitude of the revenue decline combined with net losses and the CEO's reduction of his position near the high end of the annual range suggest pressure on operational performance and may reflect uncertainty about the company's near-term trajectory.